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Abstract 
Selected synthetic dipeptides and milk protein hydrolysates were evaluated for their dipeptidyl peptidase IV (DPP-
IV) inhibitory properties, and their superoxide (SO) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging 
activities. DPP-IV inhibition was seen with eight out of the twelve dipeptides and 5 of the twelve hydrolysates 
studied. Trp-Val inhibited DPP-IV, however, inhibition was not observed with the reverse peptide Val-Trp. The most 
potent hydrolysate inhibitors were generated from casein (CasH2) and lactoferrin (LFH1). Two Trp containing 
dipeptides, Trp-Val and Val-Trp, and three lactoferrin hydrolysates scavenged DPPH. The dipeptides had higher SO 
EC50 values compared to the milk protein hydrolysates (arising from three lactoferrin and one whey protein 
hydrolysates). Higher molecular mass fractions of the milk protein hydrolysates were associated with the SO 
scavenging activity. Trp-Val and one lactoferrin hydrolysate (LFH1) were multifunctional displaying both DPP-IV 
inhibitory and antioxidant (SO and DPPH scavenging) activities. These compounds may have potential as dietary 
ingredients in the management of type 2 diabetes by virtue of their ability to scavenge reactive oxygen species and to 
extend the half-life of incretin molecules. 
 
Key words: dipeptidyl peptidase IV inhibitors, 2,2-diphenyl-1-picrylhydrazyl (DPPH). 
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1. Introduction 
The worldwide incidence of type2 diabetes is increasing. It was estimated in 2000 that there were 
171 million diabetics while incidences for 2030 are estimated to reach 366 million people [45]. 
Different strategies have been developed to help in the management of type 2 diabetes; one of 
which is inhibition of dipeptidyl peptidase IV (DDP-IV). Incretins such as glucose dependent 
insulinotropic peptide (GIP) and more particularly glucagon-like peptide-1 (GLP-1) can enhance 
insulin secretion from pancreatic beta cells in the presence of glucose in vivo [2, 42]. However, 
GLP-1 and GIP can be degraded by DDP-IV, resulting in major losses in the bioactive properties 
of these incretins. DDP-IV is located at the surface of various cells and can also be found in a 
soluble form in the circulation [2]. An increase in circulating GLP-1 by a factor 4 to 6 has been 
reported in vivo following the utilization of DDP-IV drug inhibitors [27]. DDP-IV inhibitors are 
reported to protect GLP-1 and GIP from enzymatic degradation and therefore can increase their 
half-life, resulting in a prolonged action in vivo [2]. Peptide-like DDP-IV inhibitors such as 
vildagliptin and saxagliptin [17] have been shown to normalize blood glucose concentration in 
type 2 diabetic subjects [27]. However, contradictory results are also reported in the literature 
with some studies indicating no direct correlation between the insulinotropic properties of DDP-
IV inhibitors and plasma GLP-1 levels. This suggests that other incretins and neuropeptides also 
play a role in the regulation of blood glucose homeostasis in the presence of DDP-IV inhibitors 
[27].  
 
Peptide inhibitors of DPP-IV having Xaa-Pro, Pro-Xaa or Xaa-Ala (with Xaa an amino acid 
residue) sequences have been reported in the literature [46]. Furthermore, various studies have 
highlighted the possibility of using food proteins as natural sources of DDP-IV inhibitory 
peptides. Milk proteins, particularly, milk protein-derived peptides and amino acids have also 
been linked with the regulation of postprandial glycaemia and insulin secretion in 
normoglycaemic and type 2 diabetic subjects [6, 8, 23, 24, 26, 32]. Peptides derived from -
lactoglobulin have been shown to possess DDP-IV inhibitory activity in vitro [42, 43]. 
Furthermore, the DDP-IV inhibitory peptide Leu-Pro-Glu-Arg-Ile-Pro-Pro-Leu from Gouda-type 
cheese induced a significant reduction of blood glucose in rats following a glucose challenge 
[44]. Similarly, a DPP-IV inhibitory tryptic digest of -lactoglobulin induced a decrease in blood 
glucose level in mice following an oral glucose tolerance test when administered orally at 300 
mg/kg body weight [43]. More recently, an in silico approach has been utilized to identify 
potential dietary protein precursors of DDP-IV inhibitory peptides [18]. 
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In type 2 diabetic subjects, the natural antioxidant protective systems including superoxide 
dismutase, glutathione (GSH) peroxidase and catalase may be compromised due to an overall 
increase in oxidative stress. It is well recognized that cardiovascular and renal disease can 
develop as secondary complications in subjects suffering from type 2 diabetes and insulin 
resistance syndrome [10, 12]. Different studies have demonstrated the anti-oxidative potential of 
milk proteins and peptides [3, 20, 31, 36, 38, 41]. Whey protein hydrolysates can help decrease 
oxidative stress by their radical scavenging activity and by their ability to increase the production 
of antioxidant enzymes in vivo [13, 21, 31]. Similarly, caseins and casein-derived peptides have 
been associated with radical-scavenging properties in vitro [1, 9, 15, 41] and with their ability to 
increase cellular catalase activity and GSH levels in human lymphocyte (Jurkat) cells [30]. More 
recently we have reported on two dipeptides, Val-Trp and Val-Trp, and different lactoferrin 
hydrolysates which can inhibit xanthine oxidase (XO) in vitro [28]. 
The aim of this study was to evaluate the potential of selected dipeptides for their antioxidant (SO 
and DPPH scavenging) activity and for their DDP-IV inhibitory properties. In addition, a range of 
milk protein hydrolysates was also evaluated for their antioxidant and DPP-IV inhibitory 
properties. 
2. Material and methods 
2.1. Reagents 
The synthetic dipeptides Val-Trp, Trp-Val, Ala-Leu, Asp-Lys, Glu-Lys, Gly-Leu, Ser-Leu, Ser-
Phe and Val-Ala were obtained from Bachem (Bubendorf, Switzerland) while Phe-Leu, His-Leu, 
Gly-Gln, Trp and Val were obtained from Sigma-Aldrich (Dublin, Ireland). Sodium phosphate 
monobasic, sodium phosphate dibasic, ethylenediamine tretracetic acid (EDTA), 
Tris(hydroxymethyl)aminomethane (TRIS), β-nicotinamide adenine dinucleotide (NADH), 
phenazine methosulfate (PMS), nitrotetrazolium blue (NBT), 2,2-diphenyl-1-picrylhydrazyl 
(DPPH), 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox
TM
), Gly-Pro-pNA, 
diprotin A (Ile-Pro-Ile), trifluoroacetic acid (TFA), ethanol, porcine DPP-IV (≥10 units/mg 
protein) and bovine superoxide dismutase (SOD ≥ 3000 units/mg) were obtained from Sigma 
Aldrich (Dublin, Ireland). Hydrochloric acid, sodium hydroxide, HPLC grade water and 
acetonitrile (ACN) were from VWR (Dublin, Ireland). Whey proteins (WP), caseins (Cas), and 
lactoferrin (LF) were obtained from commercial suppliers. 
2.2. Methods 
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2.2.1. Hydrolysis of milk protein substrates 
Hydrolysis of the milk protein substrates was carried out with food-grade commercial gastro-
intestinal preparations essentially as described by Spellman et al. [39]. Five WP (WPH1 to 
WPH5), four Cas (CasH1 to CasH4) and three LF (LFH1 to LFH3) hydrolysates were 
manufactured. The starting milk protein substrates were suspended at 10 % (w/w) on a protein 
basis in water and dispersed under agitation at 50C for 1 h using an overhead stirrer (Heidolph 
RZR 1, Germany) and hydrolysed at 50°C for 240 min. A control sample without enzyme was 
removed from the protein dispersion and maintained at 50°C for the duration of the hydrolysis 
reaction. The enzyme was inactivated by heating the hydrolysate samples at 90°C for 20 min. 
Hydrolysates were freeze-dried (FreeZone 18L, Labconco, Kansas City, U.S.A.) and stored at -
20°C until further analysis. 
2.2.3. Reversed-phase ultra-performance liquid chromatography of milk protein 
hydrolysates 
The starting substrates and corresponding hydrolysates were analysed by liquid chromatography 
using an ultra-performance liquid chromatograph (UPLC Acquity - Waters, Dublin, Ireland) as 
described by Nongonierma and FitzGerald [28]. 
2.2.4. DPPH radical scavenging assay  
The DPPH assay was used to determine the proton radical scavenging properties of the dipeptides 
and milk protein hydrolysates. Test samples (dipeptides and hydrolysates) were dispersed in 
HPLC grade water at concentrations ranging from 1.25 × 10
-3
 to 1.25 mg.mL
-1
. The DPPH 
scavenging assay was carried out essentially according to Liu et al. [20]. The test samples 
(50L) were pipetted onto a 96 well microplate (Sarstedt, Dublin, Ireland) containing a DPPH 
(final concentration 0.088 mM) solution in 50 % (v/v) ethanol. The microplate was incubated at 
37C for 60 min in a microplate reader (Biotek Synergy HT, Winoosky, VT, USA), absorbance 
of the DPPH radical was monitored at 517 nm. Each sample was analysed in triplicate. Trolox 
was used as a positive control. Scavenging of the DPPH radical was determined with respect to a 
control containing no scavenger (DPPH solution added with 50 L water) as described by Liu et 
al. [20]. The DPPH scavenging EC50 values (concentration of active compound required to 
observe 50 % DPPH scavenging) were determined by plotting the percentage of DPPH 
scavenging as a function of the concentration of test compound. 
2.2.5. Superoxide radical scavenging assay 
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The test samples (dipeptides and hydrolysates) were dispersed in HPLC grade water at 
concentrations ranging from 5.0 × 10
-3
 to 1.0 mg.mL
-1
. The superoxide (SO) scavenging assay 
was carried out following the method of Ewing and Janero [4]. Test samples (25L) were 
pipetted onto a 96 well microplate containing NADH (final concentration 78.4M) and NBT 
(final concentration 49.6M). All the reagents and samples were diluted in 0.1 mM EDTA in 50 
mM phosphate buffer pH 7.4. The negative control contained the same reagents, except that the 
test sample was replaced by a solution of 0.1 mM EDTA in 50 mM phosphate buffer pH 7.4 (25 
L). The reaction was initiated by adding 25 L of PMS (final concentration 3.3 M). 
Superoxide dismutase (SOD) was used as a positive control for radical scavenging. Each sample 
was analysed in triplicate. The microplate was incubated at 25C for 60 min in a microplate 
reader; absorbance of the reduced NBT was monitored at 560 nm. The SO scavenging EC50 
values were determined by plotting the percentage SO scavenged as a function of the 
concentration of test compound. 
2.2.6. DPP-IV inhibition assay 
The test samples (dipeptides and hydrolysates) were dispersed in HPLC grade water at 
concentrations ranging from 12.5 × 10
-3
 to 6.3 mg.mL
-1
. The DPP-IV inhibition assay was carried 
out as described by Lacroix and Li-Chan [17]. Test samples (50L) were pipetted onto a 96 well 
microplate containing Gly-Pro-pNA, the reaction substrate (final concentration 0.2 mM). The 
negative control contained 100 mM Tris-HCl buffer pH 8.0 (50L) and the reaction substrate 
Gly-Pro-pNA. The reaction was initiated by the addition of DPP-IV (final concentration 0.0025 
units/mL). All the reagents and samples were diluted in 100 mM Tris-HCl buffer pH 8.0. 
Diprotin A was used as a positive control. Each sample was analysed in triplicate. The microplate 
was incubated at 37C for 60 min in a microplate reader, absorbance of the released pNA was 
monitored at 405 nm. The DPP-IV IC50 values (concentration of active compound required to 
observe 50 % DPP-IV inhibition) were determined by plotting the percentage of inhibition as a 
function of the concentration of test compound. The mode of inhibition of the different 
compounds was investigated using Lineweaver and Burk analysis by measuring the initial rate of 
the reaction at different Gly-Pro-pNA concentrations ranging between 0.2 and 0.6 mM without 
inhibitors and in the presence of peptides or hydrolysates at their IC50 concentrations. Km and 
Vmax values were deducted from the Lineweaver and Burk double reciprocal plots. 
2.2.7. Statistical analysis 
Means comparison was carried out with a one way ANOVA followed by a Student Newman-
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Keuls test using SPSS (version 9, SPSS Inc., Chicago, IL, USA) at a significance level P < 0.05. 
For the Lineweaver and Burk plots, experimental data was fitted by linear regression using SPSS. 
3. Results 
3.1. Superoxide scavenging activity of dipeptides and milk protein hydrolysates 
Of the twelve dipeptides studied, scavenging activity for superoxide radicals was seen with nine 
dipeptides (Table 1). Three dipeptides (Gly-Gln, Asp-Lys and Ser-Phe) did not scavenge SO 
radicals. A wide range of EC50 values were found depending on dipeptide sequence with the 
highest values obtained with Val-Ala and His-Leu (> 370 mM) and the lowest values with Ala-
Leu. Twelve different milk protein hydrolysates were evaluated for their ability to scavenge 
superoxide radicals (Table 1). Scavenging activity was found with 4 of the hydrolysates studied. 
Three of the hydrolysates were generated from LF and one from WP. TheEC50 values ranged 
from 0.10 ± 0.01 to 0.41 ± 0.01 mg.mL
-1
. The EC50 values obtained for the four milk protein 
hydrolysates were lower (on a weight basis) than that of the dipeptides studied (Table 1). These 
results indicate that the hydrolysates were more potent, at least on a unit weight basis, than the 
dipeptides for SO scavenging. This may be due to the fact that a certain peptide chain length is 
required to observe scavenging activity. This was further confirmed by the EC50 values obtained 
for ultrafiltered fractions of WPH1 where the 5 kDa permeate and retentate had an EC50 of 0.37 ± 
0.01 and 0.14 ± 0.01 mg. mL
-1
, respectively (Table 1). 
3.2. DPPH scavenging activity of dipeptides and milk protein hydrolysates 
With the exception of Val-Trp and its reverse peptide Trp-Val, the different dipeptides studied 
showed no activity for scavenging of DPPH radicals (Table 2). Differences were seen for the 
EC50 of both peptides with Trp-Val (242.0 ± 0.1 M) being significantly more potent than Val-
Trp (654.2 ± 21.0 M). The amino acid constituents of these dipeptides were evaluated for their 
DPPH scavenging activity. Scavenging of DPPH with Val was relatively low (4.9 ± 1.8 % 
scavenged at 0.06 mg.mL
-1
) whereas Trp (47.3 ± 3.8 % scavenged at 0.06 mg.mL
-1
) behaved as a 
good scavenger for DPPH having an EC50 of 358.5 ± 0.3 M (Table 2). All 12 hydrolysates 
studied were able to scavenge DPPH radicals. However, this antioxidant activity was not higher 
than that of the unhydrolysed milk protein (negative control) with the exception of LF (data not 
shown). All three LF hydrolysates studied displayed a scavenging activity for DPPH radicals. 
The EC50 values determined for the LF hydrolysates were 5 to 10 times higher than that of Trp, 
Val-Trp and Trp-Val (Table 2). 
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3.3. DPP-IV inhibition of dipeptides and milk protein hydrolysates 
DPP-IV inhibition was seen with 8 of the dipeptides studied (Table 3) of which 5 could be 
released from milk according to in silico analysis using the Peptide Cutter Program [28]. The 
DPP-IV IC50 values for the dipeptides ranged from 65.69 ± 2.95 to 3216.73 ± 2.12 M for Val-
Trp and Gly-Leu, respectively (Table 3). The IC50 value for Diprotin A (8.49 ± 0.15 M) was 
about 15 times less than that of the most potent dipeptide studied (Trp-Val). It is interesting to 
note that the reverse peptide Val-Trp did not inhibit DPP-IV. Five of the milk protein 
hydrolysates studied were able to inhibit DPP-IV. The most potent inhibitors were LFH1 and 
CasH2 (Table 3), their comparative inhibitory activity was not significantly different (P ≥ 0.05). 
The dose-response curves obtained for three dipeptides (Trp-Val, His-Leu and Val-Ala) and three 
hydrolysates (CasH1, WPH2 and LFH1) are illustrated on Fig. 1. The IC50 values (< 0.66 mg.mL
-
1
) obtained with the dipeptides were always lower than that of the milk protein hydrolysates 
studied, with IC50 values for the hydrolysates being between 1.4 to 40 times higher than that of 
the dipeptides. The RP-UPLC profiles of hydrolysates manufactured from 3 different starting 
substrates (Cas, WP and LF) are illustrated in Fig. 2. As expected, major peptide compositional 
differences were seen between these hydrolysates (CasH1, WPH2 and LFH1) due to different 
peptide sequences being released from these substrates. However, apart from these differences, 
all three hydrolysates displayed similar DPP-IV IC50 values (P ≥ 0.05). Lineweaver and Burk 
plots allowed study of the mode of inhibition of the different dipeptides and hydrolysates. The 
double reciprocal plots for CasH1, WPH2 and LFH1 are illustrated on Fig. 3. For all 
hydrolysates, there was no significant difference in Vmax (P ≥ 0.05) in the presence and absence 
of inhibitor. However, Km values were significantly different (P < 0.05) in the presence and 
absence of inhibitor. These results indicate that the different hydrolysates studied behaved as 
competitive inhibitors of DPP-IV. Similarly, the dipeptides behaved as competitive inhibitors of 
DPP-IV with the exception of Trp-Val which behaved as a non-competitive type inhibitor (Table 
3). 
4. Discussion 
Power et al. [33] recently reviewed the antioxidant properties of peptides with a particular focus 
on milk-derived peptides and hydrolysates. Since reactive oxidative species (ROS) are found both 
in the intracellular and extracellular compartments within the human body, it is conceivable that 
different antioxidative peptide structures may function in these compartments. Low molecular 
mass peptides, such as carnosine (Ala-His) and GSH (Cys-Glu-Gly), have been shown to act as 
antioxidants within cells whereas larger molecular mass peptides (which may be present within 
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hydrolysates) can display their antioxidative activity in the plasma [33]. The antioxidant activity 
of selected dipeptides and milk protein hydrolysates was investigated. For SO scavenging 
activity, previous results have reported SO EC50 values for dipeptides of the same order as those 
found herein. Suetsuna and Chen [40] reported SO EC50 values ranging from 2.5 to 11.9 mM for 
lysine containing dipeptides. The results herein highlight differences in scavenging activities of 
dipeptides depending on dipeptide structure, with Ala-Leu (8.60 ± 0.01 mM) being the most 
potent and Val-Ala or His-Leu (EC50 > 370 mM) the least potent. Dipeptides containing a Leu 
residue appeared to have relatively low EC50 values (< 25 mM) with the exception of His-Leu 
(EC50 > 370 mM, Table 1). A potent Leu containing casein-derived dipeptide, Glu-Leu, has 
previously been described for its high SO scavenging activity [41]. Aromatic amino acids have 
been reported to display high antioxidant activity as the radicals formed with phenol and indole 
amino acids are relatively stable due to their potential to act as hydrogen donors [3, 16, 25, 31, 
35, 36]. More specifically, Komagoe et al. [16] showed that Tyr and Trp were potent scavengers 
of SO radicals (EC50 values of 0.16 mM). However, our results show that within the 12 
dipeptides studied, Trp, His and Phe containing dipeptides do not have a high SO scavenging 
activity. It has been shown that fermented milk such as kefir is able to scavenge SO radicals [20]. 
In addition, peptic hydrolysates of casein and casein derived-peptides have been identified for 
their SO scavenging activity [41]. A potent scavenger of SO radicals has been isolated from a 
peptic digest of casein with the peptide structure Tyr-Pro-Tyr-Pro-Glu-Leu [41]. Removal of the 
amino acids at the N terminal position (Tyr, Tyr-Pro or Tyr-Pro-Tyr residues) of this peptide 
resulted in a reduction of the SO scavenging activity. However, bioactivity was restored with the 
dipeptide Glu-Leu [41]. In comparison with dipeptides, milk protein hydrolysates exhibited 
higher SO scavenging activities on a weight basis, showing lower EC50 values than the dipeptides 
(Table 1). More potent SO scavenger peptides than the ones studied may be present within these 
milk protein hydrolysates. Upon fractionation of a peptic casein hydrolysate, three fractions with 
a wide range of EC50 values from less than 0.1 to greater than 10 mg.mL
-1 
have been identified 
[41]. This suggests that potent SO scavengers can be found within milk protein hydrolysates. In 
addition enrichment of bioactive peptides following fractionation could result in an increased 
potency for SO scavenging. 
 
Various milk derived peptides have previously been reported for their DPPH radical scavenging 
activity [31, 34]. Within the 12 dipeptides studied herein only Val-Trp and Trp-Val were able to 
scavenge DPPH radicals. Different EC50 values were found for these dipeptides with Trp-Val 
being twice as potent as the reverse peptide Val-Trp. EC50 values for DPPH scavenging by 
decapeptides extracted from venison protein were around 10 M [14] and values of 98 M for 
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the casein derived peptide Tyr-Pro-Tyr-Pro-Glu-Leu and of 23.3 M for carnosine (Ala-His) [41] 
have been reported. Higher DPPH EC50 values were found with the dipeptides Val-Trp and Trp-
Val herein. However, these activities were 20-40 times less potent than Trolox. To the best of our 
knowledge, this is the first time that these dipeptides have been described for their DPPH radical 
scavenging activity. It has previously been reported that the antioxidant activity of dipeptides 
depends on the C or N terminal position of certain amino acid residues with stronger antioxidant 
activity associated with Trp-Lys compared to Lys-Trp [40]. Similarly, in this study, the dipeptide 
with Trp at the N terminus (Trp-Val) was the most potent DPPH scavenger. Previous studies 
reported differences in other bioactivities for these two dipeptides. Val-Trp, a non-competitive 
angiotensin converting enzyme (ACE) inhibitor, had an ACE inhibition IC50 value 200 times less 
than Trp-Val, a competitive inhibitor of ACE [29]. Free Trp also showed scavenging properties 
for DPPH, however, it was less potent than the dipeptide Trp-Val (Table 2). The lower anti-
oxidant activity observed for amino acids compared to peptides has been explained by their lower 
radical scavenging activity [3]. In silico analysis showed that theoretically, Val-Trp can be 
released from LF following digestion with gastrointestinal activities [28]. In agreement with these 
findings, the three LF hydrolysates evaluated showed scavenging activity for DPPH radicals. 
 
Eight out of the twelve dipeptides studied herein were shown to be DPP-IV inhibitors (Table 3). 
To the best of our knowledge, some of the dipeptides described herein have not previously been 
reported as DPP-IV inhibitors. These include Trp-Val, Ala-Leu, Glu-Lys, Gly-Leu, Ser-Leu, Phe-
Leu and His-Leu. The dipeptide Val-Ala has been identified in previous studies as an inhibitor for 
DPP-IV. This dipeptide occurs in different milk proteins including -, - and -casein, -
lactoglobulin and LF [18]. The IC50 values found for the dipeptides studied herein are of the same 
order as values reported in the literature for other DPP-IV inhibitory peptides. For example, an 
IC50 of 46 M was found for Leu-Pro-Glu-Arg-Ile-Pro-Pro-Leu and other -casein peptides had 
an IC50 value between 110 and 1500 M [44]. The most potent DPP-IV inhibitory peptide studied 
herein was Trp-Val (Table 3). Surprisingly, the reverse peptide Val-Trp did not inhibit DPP-IV. 
Similar findings as those for Val-Trp and its reverse peptide have been mentioned in another 
study, with Ile-Pro (IC50 0.41 ± 0.07 M) inhibiting DPP-IV whereas its reverse peptide Pro-Ile 
did not [11]. This result was explained by the fact the N terminal residue of the peptide plays an 
important role in the inhibition of DPP-IV [11]. Different milk protein hydrolysates have been 
reported for their DPP-IV inhibitory potential including hydrolysates of-lactoglobulin [17, 43]. 
Of 22 milk protein hydrolysates screened for their DPP-IV inhibitory potential, Lacroix and Li-
Chan [17] found that casein hydrolysates were generally more potent than WP hydrolysates with 
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the exception of a peptic whey protein hydrolysate. Out of 5 hydrolysates with DPP-IV inhibition 
herein, 2 were generated from Cas and WP and one from LF. The most potent hydrolysates in 
this study were LFH1 and CasH2 (Table 3). The higher potency of Cas hydrolysates has been 
linked to the fact that -casein is the milk protein substrate displaying the highest number of 
DPP-IV inhibitory peptide sequences (which is defined as the number of peptide sequences with 
DPP-IV inhibitory activity divided by the length of the protein) [18]. The DPP-IV IC50 values 
observed for the milk protein hydrolysates described herein are of the same order as values 
reported in the literature. IC50 values ranging from 0.075 to
 
6.4 ± 2.3 mg.mL
-1
 have previously 
been reported for various food protein-derived hydrolysates [11, 17, 19]. It is interesting to note 
that the milk protein hydrolysates were less potent on a weight basis than the dipeptides (Table 
3). This may be explained by the fact that the bioactive peptides within the milk protein 
hydrolysates may be present at relatively low concentrations [17]. As expected, the RP-UPLC 
(Fig. 2) profiles of the hydrolysates studied differed, which indicates that the peptides involved in 
the bioactive properties determined within this study were different. All hydrolysates studied 
herein were competitive inhibitors of DPP-IV. Competitive inhibition suggested a direct 
interaction between the hydrolysates and DPP-IV. It has been suggested that some milk-derived 
peptides may also behave as DPP-IV substrates, resulting in a direct interaction of the peptide 
with the active site of the enzyme [17]. Similarly, most of the dipeptides were competitive DPP-
IV inhibitors with the exception of Trp-Val which was non-competitive. Non-competitive 
inhibition of DPP-IV with peptides derived from the human immunodeficiency virus-1 (HIV) 
transactivator Tat has been reported [22]. The non-competitive inhibition was due to peptides 
binding to a secondary site different from the active site of DPP-IV. 
Trp-Val and the LF hydrolysate were both able to scavenge DPPH and SO radicals, and were also 
able to inhibit DPP-IV. To the best of our knowledge, this is the first time that an LF hydrolysate 
has been reported for its DPP-IV inhibitory activity. Trp-Val and LF hydrolysates have recently 
been described for their XO inhibitory properties [28]. This result is of interest as Trp-Val and 
LFH1 may act as multifunctional components which could modulate different targets beneficial, 
for example, in the management of type 2 diabetes. Intestinal transport of intact peptides and 
even proteins is reported to occur in vivo [7]. Hydrophobic short peptide sequences from milk 
such as Leu-Trp, Phe-Tyr and Ile-Tyr, Ile-Pro-Pro could reach the circulation without being 
degraded in the gastrointestinal tract [5]. Furthermore, dipeptides with hydrophobic 
characteristics such as Trp-Val may be bioavailable especially since hydrophobic peptides have 
been associated with a high trans-epithelial permeation through a caco-2 cell monolayer [37]. 
Further studies are needed to validate that the in vitro bioactive properties described herein 
pertain in vivo. 
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Conclusion 
Protein hydrolysates and dipeptides which can be released by the action of food-grade 
gastrointestinal enzyme preparations on milk proteins behave as scavengers of DPPH and 
superoxide radicals. In addition, eight dipeptides were shown to inhibit DPP-IV of which five 
could in theory be released by the action of gastro-intestinal enzyme activities on milk proteins. 
An LF-derived hydrolysate (LFH1) and Trp-Val may act as multifunctional agents in the 
management of type 2 diabetes. Both components reduce oxidative species (SO and DPPH 
scavenging properties) and inhibit DPP-IV activity in vitro in a dose-dependent manner. 
Identification of the peptides within the milk protein hydrolysates presented herein would help to 
better understand the origin of the DPP-IV inhibition properties of these food-grade hydrolysates. 
Future in vivo studies on these components are required to validate the in vitro data and to 
confirm the bioavailability and bioactivity of these milk protein hydrolysates and dipeptides in 
humans. 
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Table captions 
 
Table 1 Inhibitory concentration inducing 50 % scavenging (EC50) for superoxide (SO) radicals with milk derived 
dipeptides, lactoferrin (LF) and whey protein (WP) hydrolysates. 
 
Table 2 Inhibitory concentration inducing 50 % scavenging (EC50) for 2,2-Diphenyl-1-picrylhydrazyl (DPPH) 
radicals with Trp, Trp-Val, Val-Trp and lactoferrin (LF) hydrolysates 
 
Table 3 Inhibitory concentration inducing 50 % inhibition (IC50) for dipeptidyl peptidase IV (DPP-IV) in the 
presence of dipeptides and milk protein hydrolysates. LFH: lactoferrin hydrolysate, CasH: casein hydrolysate and 
WPH: whey protein hydrolysate. 
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Table 1 
Compound SO EC50 (mM)
*
 SO EC50 (mg.mL
-1
)
*
 
Glu-Lys 45.16 ± 0.02
d
 9.18 ± 0.01
g
 
Gly-Leu 20.73 ± 0.01
c
 3.90 ± 0.01
f
 
Ala-Leu 8.60 ± 0.01
a
 1.74 ± 0.01
e
 
Val-Ala > 370
g
 72.71 ± 0.01
i
 
Trp-Val 131.02 ± 0.01
e
 39.75 ± 0.01
h
 
Val-Trp 114.52 ± 0.01
e
 34.75 ± 0.01
h
 
Ser-Phe 163.54 ± 0.01
f
 41.26 ± 0.01
h
 
Phe-Leu 13.81 ± 0.01
b
 3.84 ± 0.01
f
 
His-Leu > 370
g
 > 100
j
 
Ser-Leu 24.92 ± 0.01
c
 5.44 ± 0.01
f
 
LFH1 na 0.10 ± 0.01
a
 
LFH2 na 0.41 ± 0.01
d
 
LFH3 na 0.19 ± 0.01
b
 
WPH1 na 0.28 ± 0.01
c
 
WPH1-5 kDa Retentate na 0.14 ± 0.01
a
 
WPH1-5kDa Permeate na 0.37 ± 0.01
c
 
SO
†
 100.78 ± 1.29 
*
Values represent mean EC50 values ± confidence interval (P = 0.05) for quadruplicate 
determination. Within the same column, figures with different superscript letters are significantly 
different (P < 0.05). 
†
EC50 expressed in units/mL 
na: not applicable 
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Table 2 
Compound DPPH EC50 (M)
*
 DPPH EC50 (mg.mL
-
1
)
*
 
Trp-Val 242.0 ± 0.1
b
 0.07 ± 0.01
b
 
Val-Trp 654.2 ± 21.0
d
 0.20 ± 0.01
c
 
Trp 358.5 ± 0.3
c
 0.07 ± 0.01
b
 
LFH1 na 1.15 ± 0.40
d
 
LFH2 na 1.33 ± 0.01
d
 
LFH3 na 1.37 ± 0.01
d
 
Trolox 16.5 ± 2.1
a
 0.004 ± 0.001
a
 
 
*
Values represent mean EC50 values ± confidence interval (P = 0.05) for quadruplicate 
determination. Within the same column, figures with different superscript letters are significantly 
different (P < 0.05). 
na: not applicable 
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Table 3 
 
Compound DPP-IV IC50 (M)
*
 DPP-IV IC50 (mg.mL
-1
)
*
 Type of inhibition
#
 
Glu-Lys 3216.73 ± 2.12
h
 0.654 ± 0.001
f
 competitive 
Gly-Leu 2615.03 ± 612.80
g,h
 0.492 ± 0.115
f
  competitive 
Ala-Leu 882.13 ± 68.66
f
 0.178 ± 0.014
e
 competitive 
Val-Ala 168.24 ± 7.96
d
 0.032 ± 0.001
b
 competitive 
Trp-Val 65.69 ± 2.95
b
 0.020 ± 0.001
b
 non-competitive 
Phe-Leu 399.58 ± 10.81
e
 0.111 ± 0.003
d
 competitive 
His-Leu 143.19 ± 0.35
c
 0.038 ± 0.001
c
 competitive 
Ser-Leu 2517.08 ± 36.33
g
 0.549 ± 0.008
g
 competitive 
LFH1 na 1.088 ± 0.106
h,i
 competitive 
CasH1 na 1.105 ± 0.072
h
 competitive 
CasH2 na 0.882 ± 0.057
i
 competitive 
WPH1 na 1.430 ± 0.272
h
 competitive 
WPH2 na 0.999 ± 0.077
h
 competitive 
Diprotin A 4.23 ± 0.08
a
 0.0015 ± 0.0001
a
 competitive 
*
Values represent mean IC50 values ± confidence interval (P = 0.05) for quadruplicate 
determination. Within the same column, figures with different superscript letters are significantly 
different (P < 0.05). 
#
Type of inhibition determined using Lineweaver and Burk plots for the dipeptides [28] 
na: not applicable 
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Figure captions 
Fig. 1 Dose response curve for dipeptidyl peptidase IV (DDP-IV) inhibition with dipeptides (a ) Trp-Val (b) His-Leu, 
(c) Val-Ala and milk protein hydrolysates (d) CasH1, (e) WPH2 and (f) LFH1. CasH: casein hydrolysate, WPH: 
whey protein hydrolysate and LFH: lactoferrin hydrolysate. Values are the average of three determination (n=3) ± 
SD. 
 
Fig. 2 Reversed-phase ultra-performance liquid chromatography of milk protein hydrolysates with dipeptidyl 
peptidase IV (DDP-IV) inhibitory properties. (a) CasH1, (b) WPH2 and (c) LFH1. CasH: casein hydrolysate, WPH: 
whey protein hydrolysate and LFH: lactoferrin hydrolysate. 
 
Fig. 3 Lineweaver and Burk plots for dipeptidyl peptidase IV (DDP-IV) inhibition with milk protein hydrolysates (a) 
CasH1, (b) WPH2 and (c) LFH1. CasH: casein hydrolysate, WPH: whey protein hydrolysate and LFH: lactoferrin 
hydrolysate. Each data point is the average of 6 values ± SD. 
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